Bharat Biotech is set to begin the phase II and III clinical trials for COVID-19 vaccine Covaxin in children in the age group of 2 to 18 years in the next 10-12 days, informed VK Paul, Member (Health), Niti Aayog on Tuesday.
Covaxin received the DCGI nod to conduct clinical trials in children on May 11.The Niti Ayog official further stated that the anti-COVID drug ‘2DG’ developed by the Defence Research and Development Organisation (DRDO) has been granted permission for emergency use by the DCGI.
“We will examine the drug in COVID-19 National Task Force for adding it to the treatment protocol. DCGI has granted permission for emergency use,” said Paul.
Hours after Delhi Chief Minister Arvind Kejriwal stated that the new COVID variant detected in Singapore is “deadly for children” and may bring in third wave of the disease in the country, Paul reassured that children will not get serious COVID-19 infection, adding that the situation is being closely monitored and reports referring to the variant are being examined.